Literature DB >> 34906999

Allosteric Modulator KM822 Attenuates Behavioral Actions of Amphetamine in Caenorhabditis elegans through Interactions with the Dopamine Transporter DAT-1.

Osama Refai1, Shaili Aggarwal1, Mary Hongying Cheng1, Zayna Gichi1, Joseph M Salvino1, Ivet Bahar1, Randy D Blakely1, Ole V Mortensen2.   

Abstract

Aberrant dopamine (DA) signaling is associated with several psychiatric disorders, such as autism, bipolar disorder, addiction, and Parkinson's disease, and several medications that target the DA transporter (DAT) can induce or treat these disorders. In addition, psychostimulants, such as cocaine and D-amphetamine (AMPH), rely on the competitive interactions with the transporter's substrate binding site to produce their rewarding effects. Agents that exhibit noncompetitive, allosteric modulation of DAT remain an important topic of investigation due to their potential therapeutic applications. We previously identified a novel allosteric modulator of human DAT, KM822, that can decrease the affinity of cocaine for DAT and attenuate cocaine-elicited behaviors; however, whether DAT is the sole mediator of KM822 actions in vivo is unproven given the large number of potential off-target sites. Here, we provide in silico and in vitro evidence that the allosteric site engaged by KM822 is conserved between human DAT and Caenorhabditis elegans DAT-1. KM822 binds to a similar pocket in DAT-1 as previously identified in human DAT. In functional dopamine uptake assays, KM822 affects the interaction between AMPH and DAT-1 by reducing the affinity of AMPH for DAT-1. Finally, through a combination of genetic and pharmacological in vivo approaches we provide evidence that KM822 diminishes the behavioral actions of AMPH on swimming-induced paralysis through a direct allosteric modulation of DAT-1. More broadly, our findings demonstrate allosteric modulation of DAT as a behavior modifying strategy and suggests that Caenorhabditis elegans can be operationalized to identify and investigate the interactions of DAT allosteric modulators. SIGNIFICANCE STATEMENT: We previously demonstrated that the dopamine transporter (DAT) allosteric modulator KM822 decreases cocaine affinity for human DAT. Here, using in silico and in vivo genetic approaches, we extend this finding to interactions with amphetamine, demonstrating evolutionary conservation of the DAT allosteric site. In Caenorhabditis elegans, we report that KM822 suppresses amphetamine behavioral effects via specific interactions with DAT-1. Our findings reveal Caenorhabditis elegans as a new tool to study allosteric modulation of DAT and its behavioral consequences.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34906999      PMCID: PMC8969146          DOI: 10.1124/molpharm.121.000400

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  71 in total

Review 1.  The discovery of dopamine deficiency in the parkinsonian brain.

Authors:  O Hornykiewicz
Journal:  J Neural Transm Suppl       Date:  2006

2.  The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site.

Authors:  Lei Shi; Matthias Quick; Yongfang Zhao; Harel Weinstein; Jonathan A Javitch
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

3.  Molecular mechanisms of amphetamine actions in Caenorhabditis elegans.

Authors:  Lucia Carvelli; Dawn S Matthies; Aurelio Galli
Journal:  Mol Pharmacol       Date:  2010-04-21       Impact factor: 4.436

4.  The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter.

Authors:  Per Plenge; Dongxue Yang; Kristine Salomon; Louise Laursen; Iris E Kalenderoglou; Amy H Newman; Eric Gouaux; Jonathan A Coleman; Claus J Loland
Journal:  Nat Commun       Date:  2021-08-20       Impact factor: 14.919

Review 5.  Dopamine Prediction Errors in Reward Learning and Addiction: From Theory to Neural Circuitry.

Authors:  Ronald Keiflin; Patricia H Janak
Journal:  Neuron       Date:  2015-10-21       Impact factor: 17.173

Review 6.  Overview of Monoamine Transporters.

Authors:  Shaili Aggarwal; Ole V Mortensen
Journal:  Curr Protoc Pharmacol       Date:  2017-12-20

Review 7.  Impact of disruption of secondary binding site S2 on dopamine transporter function.

Authors:  Juan Zhen; Maarten E A Reith
Journal:  J Neurochem       Date:  2016-07-14       Impact factor: 5.372

8.  De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder.

Authors:  P J Hamilton; N G Campbell; S Sharma; K Erreger; F Herborg Hansen; C Saunders; A N Belovich; M A Sahai; E H Cook; U Gether; H S McHaourab; H J G Matthies; J S Sutcliffe; A Galli
Journal:  Mol Psychiatry       Date:  2013-08-27       Impact factor: 15.992

9.  Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue.

Authors:  Yongfang Zhao; Daniel S Terry; Lei Shi; Matthias Quick; Harel Weinstein; Scott C Blanchard; Jonathan A Javitch
Journal:  Nature       Date:  2011-04-24       Impact factor: 49.962

10.  Extension of the Caenorhabditis elegans Pharyngeal M1 neuron axon is regulated by multiple mechanisms.

Authors:  Osama Refai; Patricia Rohs; Paul E Mains; Jeb Gaudet
Journal:  G3 (Bethesda)       Date:  2013-11-06       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.